X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will operate under the name Yumanity Therapeutics. Yumanity’s lead product candidate is YTX-7739, which is currently in Phase 1 clinical development for the treatment and disease modification of Parkinson’s disease.
Lead Product(s): YTX-7739
Therapeutic Area: Neurology Product Name: YTX-7739
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Yumanity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 23, 2020
Details:
The combined company will leverage their common scientific expertise in protein misfolding, and will work to advance Yumanity’s lead candidate YTX-7739, currently in Phase 1 clinical development for the treatment and disease modification of Parkinson’s disease.
Lead Product(s): YTX-7739
Therapeutic Area: Neurology Product Name: YTX-7739
Highest Development Status: Phase IProduct Type: Undisclosed
Recipient: Yumanity Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger August 24, 2020
Details:
In in vitro studies conducted at Calibr, the drug discovery division of Scripps Research, PTI-129 demonstrated the potential to reduce viral protein production in host cells by activating the adaptive branches of the UPR pathway and reducing the levels of misfolded proteins.
Lead Product(s): PTI-129
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2020
Details:
Dutch regulatory board supportive of choices program, which may lead toward market authorization for treatment of people with CF Choices protocol receives 'high strategic priority' score from CTN.
Lead Product(s): Dirocaftor,Posenacaftor,Nesolicaftor
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2020
Details:
The organoid system is a European Commission-funded global project that has attracted a selected number of drug developers and leading CF experts to create a blueprint for customized CF therapy.
Lead Product(s): Dirocaftor,Posenacaftor,Nesolicaftor
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
